Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan

Abstract

Both vaccines have a different epidemiological impact with an increased number of CC-related lesions potentially prevented for the BV because of additional cross-protection. In the Taiwanese setting, HPV mass vaccination using the BV was estimated to dominate vaccination using the QV.

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

“…However, the quadrivalent vaccine was more favorable if anogenital warts cases were included in the analysis (ICER e16,300/QALY). These results are in line with the results from various other studies [55,56], which mentioned that mass HPV vaccination with the quadrivalent vaccine was slightly dominated by the bivalent vaccine. However, long-term results on crossprotection have yet to be provided.…”

Cost-Effectiveness Analysis of HPV Vaccination: Comparing the General Population with Socially Vulnerable Individuals

“…Through the implementation of a national policy to support vaccination of socially vulnerable populations rather than the general population, we expect to see a decrease in the economic burden caused by HPV infections (Liao et al, 2009;Demarteau et al, 2012;da Fonseca et al, 2013). Of course, it is difficult to determine the actual economic value of HPV vaccination from the results of this study; thus, further studies should be undertaken.…”

Does it matter? Discounting and its role in the cost-effectiveness of preventative interventions. The case of HPV vaccination

“…2 Input parameters and assumptions were retrieved from the literature, public databases and expert opinion. Clinically, the protection offered by the 3-and 2-dose bHPV schedules against HPV-16 and HPV-18 was assumed to be identical based on clinical trial results and set at 98% for both vaccines.…”

“…HPV-31/33/35/39/45/51/52/56/58/59, see Table 1 for details). 2 The quality of life detriment for each endpoint used in the model is reported in Table 1. A lifelong duration and a 2-dose vaccination schedule were assumed for each vaccine and the same price per dose at £80.50.…”

“…trivalent flu vaccine), the profiles of bHPV and qHPV differ markedly, which has triggered comparative assessment on costs and benefits of the two vaccines. 2 In the UK, the HPV vaccination programme started in 2008 using the bHPV. In 2011, the UK government changed the criteria for the tender renewal, which led to GSK not submitting for the tender.…”